FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097414305> ?p ?o ?g. }

• W3097414305 endingPage "44" @default.
• W3097414305 startingPage "43" @default.
• W3097414305 abstract "Background: BCMA targeted immunotherapy has yielded promising results for relapsed/refractory multiple myeloma (RRMM). TNB-383B is a BCMA x CD3 bispecific T-cell redirecting antibody incorporating a unique anti-CD3 moiety that preferentially activates effector over regulatory T-cells and uncouples cytokine release from anti-tumor activity, as well as 2 heavy-chain-only anti-BCMA moieties for a 2:1 tumor associated antigen to CD3 stoichiometry. Results from the ongoing phase 1 dose escalation and expansion First-in-Human (FIH) study of TNB-383B are presented (NCT03933735). Methods: Eligible patients have RRMM and have been exposed to at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Patients have been treated with escalating doses of TNB-383B infused IV over 1-2 hours Q3W (without step-up dosing). The primary objectives are to determine the safety/tolerability and clinical pharmacology of TNB-383B and to identify the MTD/RP2D. The study used a 3+3 design for dose escalation, with additional patients enrolled on cleared dose levels. Patients on earlier dose cohorts were allowed to increase to the highest cleared dose with investigator consensus. Responses were assessed by IMWG criteria and Adverse Events (AEs) were graded according to CTCAE v5.0. Minimal residual disease (MRD) assessment was performed via NGS on bone marrow samples in patients achieving a complete response (CR). Results: As of 13 July 2020, 38 subjects have been dosed with TNB-383B (0.025 - 40 mg). Demographics and disease characteristics at study entry are summarized in Table 1. The most common Gr 3/4 AEs were anemia (6/38; 16%) and thrombocytopenia (5/38; 13%). The most common drug-related AEs were CRS (8/38; 21%) and headache (5/38; 13%). One case of Gr 2 CRS was observed at 0.075 mg; all other CRS events were seen at 5.4 mg and above. Cases of CRS were grade 1 (5/8) or 2 (3/8) and occurred only after the first dose of TNB-383B. All but 3 subjects were managed with fluids and acetaminophen (the other 3 received 1 dose each of tocilizumab). One DLT, Gr3 confusion that resolved within 6 hours without sequelae was seen at the 20 mg dose in an additional patient enrolled on this cohort. No IRRs were observed. Dose modification was necessary in 1 subject for Gr 3 neutropenia associated with CRS; the subject escalated to their full dose after tolerating subsequent doses without incident. 5 subjects died from their underlying disease during follow-up. 15 subjects discontinued treatment, all of them for progressive disease. Preliminary PK data support Q3W dosing of TNB-383B. Activity was observed in one patient each at 0.2 mg and 1.8 mg; at doses of 5.4 - 40 mg an ORR of 52% (12/23) was observed. Depth and duration of response are summarized in Table 2. Conclusions: TNB-383B is well tolerated at doses up to 40 mg, without the need for step/split dosing. A preliminary ORR of 52% (12/23) was observed at doses ≥ 5.4 mg, including deep (6 PR / 3 VGPR / 3 CR) and durable (up to 24 weeks) responses despite dosing only every 3 weeks. Enrollment into the dose escalation arm is ongoing; updated data will be presented at the meeting. Disclosures Rodriguez: BMS, Takeda, Amgen: Consultancy, Speakers Bureau. D'Souza:Amgen: Research Funding; Akcea: Consultancy; Pfizer: Consultancy; Teneobio: Research Funding; Imbrium: Consultancy; Merck: Research Funding; Janssen: Consultancy. Shah:GSK, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx, Kite, Karyopharm: Consultancy; BMS, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, Nektar: Research Funding. Voorhees:Bristol-Myers Squibb: Other: Personal fees; Adaptive Biotechnologies: Other: Personal fees; Novartis: Other: Personal fees; Celgene: Other: Personal fees; Janssen: Other: Personal fees; Oncopeptides: Other: Personal fees; TeneoBio: Other: Personal fees; Levine Cancer Institute, Atrium Health: Current Employment. Buelow:Teneobio, Inc.: Current Employment, Current equity holder in private company. Kumar:Karyopharm: Consultancy; Tenebio: Other, Research Funding; Sanofi: Research Funding; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Genecentrix: Consultancy; Dr. Reddy's Laboratories: Honoraria; Adaptive Biotechnologies: Consultancy; Merck: Consultancy, Research Funding; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; BMS: Consultancy, Research Funding; Cellectar: Other; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Carsgen: Other, Research Funding; Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Novartis: Research Funding; MedImmune: Research Funding; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Kite Pharma: Consultancy, Research Funding." @default.
• W3097414305 created "2020-11-09" @default.
• W3097414305 creator A5013281585 @default.
• W3097414305 creator A5026151069 @default.
• W3097414305 creator A5026574827 @default.
• W3097414305 creator A5033256635 @default.
• W3097414305 creator A5036605555 @default.
• W3097414305 creator A5053904944 @default.
• W3097414305 creator A5071438752 @default.
• W3097414305 date "2020-11-05" @default.
• W3097414305 modified "2023-09-29" @default.
• W3097414305 title "Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma" @default.
• W3097414305 doi "https://doi.org/10.1182/blood-2020-139893" @default.
• W3097414305 hasPublicationYear "2020" @default.
• W3097414305 type Work @default.
• W3097414305 sameAs 3097414305 @default.
• W3097414305 citedByCount "43" @default.
• W3097414305 countsByYear W30974143052021 @default.
• W3097414305 countsByYear W30974143052022 @default.
• W3097414305 countsByYear W30974143052023 @default.
• W3097414305 crossrefType "journal-article" @default.
• W3097414305 hasAuthorship W3097414305A5013281585 @default.
• W3097414305 hasAuthorship W3097414305A5026151069 @default.
• W3097414305 hasAuthorship W3097414305A5026574827 @default.
• W3097414305 hasAuthorship W3097414305A5033256635 @default.
• W3097414305 hasAuthorship W3097414305A5036605555 @default.
• W3097414305 hasAuthorship W3097414305A5053904944 @default.
• W3097414305 hasAuthorship W3097414305A5071438752 @default.
• W3097414305 hasBestOaLocation W30974143051 @default.
• W3097414305 hasConcept C121608353 @default.
• W3097414305 hasConcept C126322002 @default.
• W3097414305 hasConcept C143998085 @default.
• W3097414305 hasConcept C197934379 @default.
• W3097414305 hasConcept C203014093 @default.
• W3097414305 hasConcept C2776364478 @default.
• W3097414305 hasConcept C2777478702 @default.
• W3097414305 hasConcept C2777701055 @default.
• W3097414305 hasConcept C2778020697 @default.
• W3097414305 hasConcept C2778375690 @default.
• W3097414305 hasConcept C2778461978 @default.
• W3097414305 hasConcept C2778524551 @default.
• W3097414305 hasConcept C2779823535 @default.
• W3097414305 hasConcept C2780007613 @default.
• W3097414305 hasConcept C2780850621 @default.
• W3097414305 hasConcept C2909962599 @default.
• W3097414305 hasConcept C3875195 @default.
• W3097414305 hasConcept C71924100 @default.
• W3097414305 hasConceptScore W3097414305C121608353 @default.
• W3097414305 hasConceptScore W3097414305C126322002 @default.
• W3097414305 hasConceptScore W3097414305C143998085 @default.
• W3097414305 hasConceptScore W3097414305C197934379 @default.
• W3097414305 hasConceptScore W3097414305C203014093 @default.
• W3097414305 hasConceptScore W3097414305C2776364478 @default.
• W3097414305 hasConceptScore W3097414305C2777478702 @default.
• W3097414305 hasConceptScore W3097414305C2777701055 @default.
• W3097414305 hasConceptScore W3097414305C2778020697 @default.
• W3097414305 hasConceptScore W3097414305C2778375690 @default.
• W3097414305 hasConceptScore W3097414305C2778461978 @default.
• W3097414305 hasConceptScore W3097414305C2778524551 @default.
• W3097414305 hasConceptScore W3097414305C2779823535 @default.
• W3097414305 hasConceptScore W3097414305C2780007613 @default.
• W3097414305 hasConceptScore W3097414305C2780850621 @default.
• W3097414305 hasConceptScore W3097414305C2909962599 @default.
• W3097414305 hasConceptScore W3097414305C3875195 @default.
• W3097414305 hasConceptScore W3097414305C71924100 @default.
• W3097414305 hasIssue "Supplement 1" @default.
• W3097414305 hasLocation W30974143051 @default.
• W3097414305 hasOpenAccess W3097414305 @default.
• W3097414305 hasPrimaryLocation W30974143051 @default.
• W3097414305 hasRelatedWork W2149486731 @default.
• W3097414305 hasRelatedWork W2285430992 @default.
• W3097414305 hasRelatedWork W2400769328 @default.
• W3097414305 hasRelatedWork W2892984448 @default.
• W3097414305 hasRelatedWork W2991695207 @default.
• W3097414305 hasRelatedWork W3034859929 @default.
• W3097414305 hasRelatedWork W3097414305 @default.
• W3097414305 hasRelatedWork W4206222413 @default.
• W3097414305 hasRelatedWork W4210686872 @default.
• W3097414305 hasRelatedWork W4281551859 @default.
• W3097414305 hasVolume "136" @default.
• W3097414305 isParatext "false" @default.
• W3097414305 isRetracted "false" @default.
• W3097414305 magId "3097414305" @default.
• W3097414305 workType "article" @default.